Latest Developments in Global Soft Tissue Sarcomas Treatment Market

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Latest Developments in Global Soft Tissue Sarcomas Treatment Market

  • Pharmaceutical
  • Upcoming Report
  • Jan 2025
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

  • In May 2023, Bayer announced that Larotrectinib sulfate is currently undergoing phase II clinical trials, designed for the treatment of sarcoma with solid tumors in both adults and children
  • In June 2023, CancerVAX, Inc., the developer of a revolutionary universal cancer vaccine that utilizes the immune system to combat cancer, launched a $10 million financing round. The funds raised through an SEC-approved Reg A+ sale will help advance its groundbreaking cancer treatments. The company is collaborating with UCLA to develop targeted therapies for Ewing sarcoma, an aggressive cancer affecting young individuals' bones and soft tissues
  • In March 2022, Phio Pharmaceuticals Corp., a biotechnology firm specializing in immuno-oncology drugs based on its self-delivering RNAi therapeutic platform, announced a partnership with AgonOx, Inc. The collaboration aims to develop cancer drugs by combining AgonOx’s tumor-infiltrating T-cell technology with Phio’s RNAi platform
  • In January 2021, Pfizer announced that the European Commission had approved Vitrakvi (larotrectinib) for the treatment of advanced soft tissue sarcoma. Vitrakvi is a targeted therapy for patients whose malignancies contain a specific genetic mutation
  • In June 2021, Johnson & Johnson revealed that its drug JNJ-4528 had been approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory multiple myeloma. Though not specifically for soft tissue sarcoma, JNJ-4528 is a CAR-T cell therapy being developed for various malignancies, including certain types of sarcoma

Frequently Asked Questions

The market is segmented based on Segmentation, By Disease Type (Angiosarcoma, Dermatofibrosarcoma, Epithelioid Sarcoma, and Others), Local Recurrence Rate (Children and Adults), Treatment Type (Surgery, Radiotherapy, Chemotherapy, and Targeted Drug Therapy), End User (Hospitals, Specialty Clinics, and Others) – Industry Trends and Forecast to 2032 .
The Global Soft Tissue Sarcomas Treatment Market size was valued at USD 1.52 USD Billion in 2024.
The Global Soft Tissue Sarcomas Treatment Market is projected to grow at a CAGR of 6.49% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.